头颈部炎性肌纤维母细胞瘤研究进展

doi:10.19438/j.cjoms.2018.01.018

中国口腔颌面外科杂志 ›› 2018, Vol. 16 ›› Issue (1): 84-88.doi: 10.19438/j.cjoms.2018.01.018

头颈部炎性肌纤维母细胞瘤研究进展

彭灿邦¹, 田臻^2,*, 季彤^1,*

1.上海交通大学医学院附属第九人民医院·口腔医学院口腔颌面-头颈肿瘤科;
2.口腔病理科, 上海市口腔医学重点实验室,上海市口腔医学研究所,国家口腔疾病临床研究中心,上海 200011

收稿日期:2017-05-10 修回日期:2017-07-20 出版日期:2018-01-20 发布日期:2018-02-11
通讯作者: 季彤,E-mail：jitong70@hotmail.com;田臻,E-mail：tian0304_cn@163.com。^*共同通信作者
作者简介:彭灿邦（1992-）,男,硕士,住院医师,E-mail：Chris_Dr@163.com
基金资助:
国家自然科学基金（81672745）; 上海高校高峰高原学科建设项目（81671009）

Research progress of inflammatory myofibroblastic tumor in head and neck region

PENG Can-bang¹, TIAN Zhen², JI Tong¹

1.Department of Oromaxillofacial Head and Neck Oncology, 2.Department of Oral Pathology, Shanghai Ninth People's Hospital, College of Stomatology, Shanghai Jiao Tong University School of Medicine; Shanghai Key Laboratory of Stomatology & Shanghai Research Institute of Stomatology;; National Clinical Research Center of Stomatology. Shanghai 200011, China

Received:2017-05-10 Revised:2017-07-20 Online:2018-01-20 Published:2018-02-11

摘要/Abstract

摘要： 炎性肌纤维母细胞瘤（inflammatory myofibroblastic tumor,IMT）是中间性软组织肿瘤,是由肌纤维母细胞/纤维母细胞所组成的独特肿瘤,伴浆细胞、淋巴细胞和（或）嗜酸性粒细胞浸润。头颈部IMT临床上并不常见,所以对该疾病的治疗及预后评估尚缺乏统一标准。本文就IMT的病因、临床特点、病理特点、治疗及预后的研究进展进行综述,以期提高头颈部IMT的诊疗水平。

关键词: 炎性肌纤维母细胞瘤, 间变性淋巴瘤激酶, Cox-2抑制剂

Abstract: Inflammatory myofibroblastic tumor (IMT) is a distinctive mesenchymal neoplasm, composed of myofibroblasts/ fibroblasts, plasma cells, lymphocytes and/or infiltrating eosinophils. It is not common in the head and neck region, which resulted in the lack of standards of treatment and prognosis for the disease. This paper reviewed the current literature on the etiology, clinical features, pathology, treatment and prognosis of IMT in order to facilitate better recognition and treatment of IMT in head and neck region.

Key words: Inflammatory myofibroblastic tumor, ALK, Cox-2 inhibitor

中图分类号:

R739.8

彭灿邦, 田臻, 季彤. 头颈部炎性肌纤维母细胞瘤研究进展[J]. 中国口腔颌面外科杂志, 2018, 16(1): 84-88.

PENG Can-bang, TIAN Zhen, JI Tong. Research progress of inflammatory myofibroblastic tumor in head and neck region[J]. China J Oral Maxillofac Surg, 2018, 16(1): 84-88.

参考文献

[1] Al-Humidi A, Al-Khamiss A.Inflammatory myofibroblastic tumor arising in the external ear: unexpected location. (case report)[J]. Int J Health Sci (Qassim), 2015, 9(2): 201-205.
[2] Coffin CM, Humphrey PA, Dehner LP.Extrapulmonary inflammatory myofibroblastic tumor: a clinical and pathological survey[J]. Semin Diagn Pathol, 1998, 15(2): 85-101.
[3] Gleason BC, Hornick JL.Inflammatory myofibroblastic tumors: where are we now?[J]. J Clin Pathol, 2008, 61(4): 428-437.
[4] Mariño-Enríquez A, Wang WL, Roy A, et al.Epithelioid inflammatory myofibroblastic sarcoma: an aggressive intra-abdominal variant of inflammatory myofibroblastic tumor with nuclear membrane or perinuclear ALK[J]. Am J Surg Pathol, 2011, 35(1): 135-144.
[5] Meis JM, Enzinger FM.Inflammatory fibrosarcoma of the mesentery and retroperitoneum. A tumor closely simulating inflammatory pseudotumor[J].Am J Surg Pathol, 1991, 15(12): 1146-1156.
[6] Coffin CM, Fletcher JA.Inflammatory myofibroblastic tumor.World Health Organization classification of tumors. WHO classification of soft tissue and bone [M]. 4th Ed. Lyon: IARc Press, 2013: 83-84.
[7] Tao J, Zhou ML, Zhou SH.Inflammatory myofibroblastic tumors of the head and neck[J]. Int J Clin Exp Med, 2015, 8(2): 1604-1610.
[8] Fletcher CDM, Unni KK, Mertens F.World Health Organization classification of tumors: pathology and genetics of tumors of soft tissue and bone [M]. Lyon: IARC Press, 2002: 91-93.
[9] Mehta B, Mascarenhas L, Zhou S, et al.Inflammatory myofibroblastic tumors in childhood[J]. Pediatr Hematol Oncol, 2013, 30(7): 640-645.
[10] Coffin CM, Dehner LP, Meis-Kindblom JM.Inflammatory myofibroblastic tumor, inflammatory fibrosarcoma, and related lesions: An historical review with differential diagnostic considerations[J]. Semin Diagn Pathol, 1998, 15(2): 102-110.
[11] Hytiroglou P, Brandwein Ms, Strauchen JA, et al.Inflammatory pseudotumor of the parapharyngeal space: case report and review of the literature[J]. Head Neck, 1992, 14(3): 230-234.
[12] Coffin CM, Patel A, Perkins S, et al.ALK1 and p80 expression and chromosomal rearrangements involving 2p23 in inflammatory myofibroblastic tumor[J]. Mod Pathol, 2001, 14(6): 569-576.
[13] Yamamoto H, Yoshida A, Taguchi K, et al.ALK, ROS1 and NTRK3 gene rearrangements in inflammatory myofibroblastic tumours[J]. Histopathology, 2016, 69(1): 72-83.
[14] Morris SW, Kirstein MN, Valentine MB.Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin' s lymphoma[J]. Science, 1994, 263(5151): 1281-1284.
[15] 孟宇宏, 吴惠. ALK与ALK阳性肿瘤的病理诊断与治疗进展[J]. 诊断病理学杂志, 2014, 21(6): 361-366.
[16] Lawrence B, Perez-Atayde A, Hibbard MK, et al.TPM3-ALK and TPM4-ALK oncogenes in inflammatory myofibroblastic tumors[J]. Am J Pathol, 2000, 157(2): 377-384.
[17] Bridge JA, Kanamori M, Ma Z, et al.Fusion of the ALK gene to the clathrin heavy chain gene, CLTC, in inflammatory myofibroblastic tumor[J]. Am J Pathol, 2001, 159(2): 411-415.
[18] Cools J, Wlodarska I, Somers R, et al.Identification of novel fusion partners of ALK, the anaplastic lymphoma kinase, in anaplastic large-cell lymphoma and inflammatory myofibroblastic tumor[J]. Genes Chromosom Cancer, 2002, 34(4): 354-362.
[19] Chen ST, Lee JC.An inflammatory myofibroblastic tumor in liver with ALK and RANBP2 gene rearrangement: combination of distinct morphologic, immunohistochemical, and genetic features[J]. Hum Pathol, 2008, 39(12): 1854-1858.
[20] Yamamoto H, Kohashi K, Oda Y, et al.Absence of human herpesvirus-8 and Epstein-Barr virus in inflammatory myofibroblastic tumor with anaplastic large cell lymphoma kinase fusion gene[J]. Pathol Int, 2006, 56(10): 584-590.
[21] Takeuchi K, Soda M, Togashi Y, et al.Pulmonary inflammatory myofibroblastic tumor expressing a novel fusion, PPFIBP1-ALK: reappraisal of anti-ALK immunohistochemistry as a tool for novel ALK fusion identification[J]. Clin Cancer Res, 2011, 17(10): 3341-3348.
[22] Yoshida A, Shibata T, Tsuta K, et al.Inflammatory myofibroblastic tumour of the lung with a novel PPFIBP1-ALK fusion variant[J]. Histopathology, 2013, 63(6): 881-883.
[23] Wang X, Krishnan C, Nguyen EP, et al.Fusion of dynactin 1 to anaplastic lymphoma kinase in inflammatory myofibroblastic tumor[J]. Hum Pathol, 2012, 43(11): 2047-2052.
[24] Lovly CM, Gupta A, Lipson D, et al.Inflammatory myofibroblastic tumors harbor multiple potentially actionable kinase fusions[J]. Cancer Discov, 2014, 4(8): 889-895.
[25] Davies KD, Doebele RC.Molecular pathways: ROS1 fusion proteins in cancer[J]. Clin Cancer Res, 2013, 19(15): 4040-4045.
[26] 段衍超, 郭农建. ETV6-NTRK3 融合基因研究进展[J]. 医学综述, 2008, 14(4): 528-530.
[27] Alassiri AH, Ali RH, Shen Y,et al.ETV6-NTRK3 is expressed in a subset of ALK-Negative inflammatory myofibroblastic tumors[J]. Am J Surg Pathol, 2016, 40(8): 1051-1061.
[28] Pettinato G, Manivel JC, De Rosa N, et al.Inflammatory myofibroblastic tumor (plasma cell granuloma). Clinicopathologic study of 20 cases with immunohistochemical and ultrastructural observations[J]. Am J Clin Pathol, 1990, 94(5): 538-546.
[29] Pisciotto PT, Gray GF Jr, Miller DR.Abdominal plasma cell pseudotumor[J]. J Pediatr, 1978, 93(4): 628-630.
[30] Ong HS, Ji T, Zhang CP, et al.Head and neck inflammatory myofibroblastic tumor(IMT): evaluation of clinicopathologic and prognostic features[J]. Oral Oncol, 2012, 48(2): 141-148.
[31] 李卉, 王德玲, 刘学文, 等. 头颈部炎性肌纤维母细胞瘤的影像表现及临床特点[J]. 中国肿瘤临床, 2012, 39(24): 2094-2097.
[32] Chan JK, Cheuk W, Shimizu M.Anaplastic lymphoma kinase expression in inflammatory pseudotumors[J]. Am J Surg Pathol, 2001, 25(6): 761-768.
[33] Fisher C, Goldblum JR, Montgomery E.Calponin and h-caldesmon in sarcomas of myofibroblasts[J]. Mod Pathol, 2003, 16(4): 11A.
[34] Cook JR, Dehner LP, Collins MH, et al.Anaplastic lymphoma kinase (ALK) expression in the inflammatory myofibroblastic tumor: a comparative immunohistochemical study[J]. Am J Surg Pathol, 2001, 25(11): 1364-1371.
[35] Ma Z, Hill DA, Collins MH, et al.Fusion of ALK to the Ran-binding protein 2 (RANBP2) gene in inflammatory myofibroblastic tumor[J]. Genes Chromosomes Cancer, 2003, 37(1): 98-105.
[36] Hallberg B, Palmer RH.Crizotinib-latest champion in the cancer wars?[J]. N Engl J Med, 2010, 363(18): 1760-1762.
[37] Croegaert K, Kolesar JM.Role of anaplastic lymphoma kinase inhibition in the treatment of non-small-cell lung cancer[J]. Am J Health Syst Pharm, 2015, 72(17): 1456-1462.
[38] Minoo P, Wang HY.ALK-immunoreactive neoplasms[J]. Int J Clin Exp Pathol, 2012, 5(5): 397-410.
[39] Gaudichon J, Jeanne-Pasquier C, Deparis M, et al.Complete and repeated response of a metastatic ALK-rearranged inflammatory myofibroblastic tumor to crizotinib in a teenage girl[J]. J Pediatr Hematol Oncol, 2016, 38(4): 308-311.
[40] Butrynski JE, D'Adamo DR, Hornick JL, et al. Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor[J]. N Engl J Med, 2010, 363(18): 1727-1733.
[41] Affara NI, Coussens LM.IKKalpha at the crossroads of inflammation and metastasis[J]. Cell, 2007, 129(1): 25-26.
[42] Gasparini G, Longo R, Sarmiento R, et al.Inhibitors of cyclo-oxygenase 2: a new class of anticancer agents?[J]. Lancet Oncol, 2003, 4(10): 605-615.
[43] Smith WL, De Witt DL, Garavito RM.Cyclooxygenases: structural, cellular, and molecular biology[J]. Annu Rev Biochem, 2000, 69: 145-182.
[44] Singh B, Berry JA, Shoher A, et al.COX-2 overexpression increases motility and invasion of breast cancer cells[J]. Int J Oncol, 2005, 26(5): 1393-1399.
[45] Chow LW, Loo WT, Toi M.Current directions for COX-2 inhibition in breast cancer[J]. Biomed Pharmacother, 2005, 59(Suppl 2): S281-284.
[46] Wang G, Li J, Zhang L, et al.Celecoxib induced apoptosis against different breast cancer cell lines by down-regulated NF-κB pathway[J]. Biochem Biophys Res Commun, 2017, 490(3): 969-976.
[47] Applebaum H, Kieran MW, Cripe TP.The rationale for nonsteroidal anti-inflammatory drug therapy for inflammatory myofibroblastic tumors: a Children's Oncology Group study[J]. J Pediatr Surg, 2005, 40(6): 999-1003.
[48] Debelenko LV, Arthur DC, Pack SD, et al.Identification of CARS-ALK fusion in primary and metastatic lesions of an inflammatory myofibroblastic tumor[J]. Lab Invest, 2003, 83(9): 1255-1265.

头颈部炎性肌纤维母细胞瘤研究进展

Research progress of inflammatory myofibroblastic tumor in head and neck region

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 3

编辑推荐

Metrics

本文评价

[1]	徐晨, 马丽娟, 石尧, 文玉珍, 宋永海, 车宗刚. 腮腺区炎性肌纤维母细胞瘤1例报告及文献复习[J]. 中国口腔颌面外科杂志, 2024, 22(4): 413-416.
[2]	王灿, 张春叶, 陶晓峰, 王博成, 朱凌. 29例头颈部炎性肌纤维母细胞肿瘤的CT及MRI影像学特征分析[J]. 中国口腔颌面外科杂志, 2022, 20(5): 494-499.
[3]	杨柳笛, 黄龙, 苏彤. 泼尼松治愈下颌骨炎性肌纤维母细胞瘤1例报告[J]. 中国口腔颌面外科杂志, 2020, 18(6): 574-576.